BioSpace News Archive

Vicore’s digital therapeutic for IPF patients shows nearly 50% anxiety reduction in pilot study

Vicore Pharma Holding AB pioneering development of angiotensin II type 2 receptor agonists, announces positive results for the pilot phase of the COMPANION study.

October 6, 2022
·
4 min read
Largest study measuring extent of COVID-19 in Canadian children and teens now underway

In Canada, the vast majority of COVID-19 cases in the 0 to 18 age group have been mild or asymptomatic. This fact, combined with the reduction in routine COVID-19 laboratory testing across most of the country, means that the infection rates in children and adolescents are largely unknown.

October 6, 2022
·
4 min read
Business

Shasqi Scientific Advisor Carolyn Bertozzi Awarded Nobel Prize for the Development of Click Chemistry

Shasqi announced that the company’s scientific advisor, Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in Chemistry, alongside Morten Meldal, Ph.D., and Nobel Laureate K. Barry Sharpless, Ph.D., for the development of click chemistry and bioorthogonal chemistry.

October 6, 2022
·
3 min read
Biotech Bay

Adiso Therapeutics Provides Development Update Reflecting Strong Progress Across Its Pipeline

Adiso Therapeutics, Inc. announced that enrollment in the third cohort of its Phase 1b study of ADS051 for the treatment of moderate-to-severe ulcerative colitis is complete.

October 6, 2022
·
7 min read
Business

Mallinckrodt Announces Appointment of Susan Silbermann to its Board of Directors

Mallinckrodt plc, a global specialty pharmaceutical company, announced that it has appointed Susan Silbermann to its Board of Directors, effective October 5, 2022.

October 6, 2022
·
5 min read
Pharm Country

Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™

Zynerba Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued Patent No. 11,458,110, titled “Treatment of Fragile X Syndrome With Cannabidiol,” which includes claims directed to methods of treating Fragile X syndrome with cannabidiol.

October 6, 2022
·
5 min read
Business

SOPHiA GENETICS to Announce Financial Results for the Third Quarter of Fiscal 2022 on November 8, 2022

SOPHiA GENETICS today announced it will release its financial results for the third quarter of fiscal 2022 before U.S. markets open on Tuesday, November 8, 2022.

October 6, 2022
·
1 min read
Biotech Bay

AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease

AN2 Therapeutics, Inc. today provided an update on the ex-U.S. development plan for epetraborole in treatment-refractory Mycobacterium avium complex (MAC) lung disease, the most common form of non-tuberculous mycobacterial (NTM) lung disease.

October 6, 2022
·
5 min read
Business

NexImmune Announces Research Collaboration with National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH)

NexImmune, Inc. today announced a collaboration with the National Institute of Neurological Disorders and Stroke (NINDS), a division of the U.S. National Institutes of Health (NIH).

October 6, 2022
·
5 min read
Drug Development

Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis- Total Hip BMD Established as Primary Endpoint -

Entera Bio Ltd. conclusion of its Type C meeting and agreement from the U.S. Food and Drug Administration (FDA) that a single Phase 3 placebo-controlled study could support a New Drug Application (NDA) submission of EB613.

October 6, 2022
·
8 min read